Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Emerging Markets ETF
EEM
|
+$14.1B |
| 2 |
Invesco QQQ Trust
QQQ
|
+$1.34B |
| 3 |
Visa
V
|
+$714M |
| 4 |
VanEck Semiconductor ETF
SMH
|
+$638M |
| 5 |
HONA
Honeywell Aerospace
HONA
|
+$508M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.58B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$1.74B |
| 3 |
Apple
AAPL
|
+$1.66B |
| 4 |
Advanced Micro Devices
AMD
|
+$1.3B |
| 5 |
Amazon
AMZN
|
+$1.23B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 55.34% |
| 2 | Technology | 17.88% |
| 3 | Financials | 5.92% |
| 4 | Consumer Discretionary | 4.3% |
| 5 | Communication Services | 3.8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
3126
Alpha Metallurgical Resources
AMR
$2.21B
| $550K | ﹤0.01% |
3,333
-3,651
| -52% | -$696K |
|
3127
American Public Education
APEI
$762M
| $550K | ﹤0.01% |
10,234
-599
| -6% | -$32.9K |
|
3128
Immix Biopharma
IMMX
$785M
| $547K | ﹤0.01% |
53,056
+1,288
| +2% | +$11.9K |
|
3129
Zumiez
ZUMZ
$204M
| $546K | ﹤0.01% |
30,696
-502
| -2% | -$11.2K |
|
3130
Nurix Therapeutics
NRIX
$2.39B
| $545K | ﹤0.01% |
22,482
-1,698
| -7% | -$28.9K |
|
3131
Rigel Pharmaceuticals
RIGL
$900M
| $545K | ﹤0.01% |
13,933
-1,265
| -8% | -$39K |
|
|
NBP
3132
NovaBridge Biosciences American Depositary Shares
NBP
$160M
| $544K | ﹤0.01% |
279,019
-20,280
| -7% | -$41.4K |
|
3133
LegalZoom.com
LZ
$963M
| $543K | ﹤0.01% |
88,657
-12,132
| -12% | -$74.4K |
|
3134
Nature's Sunshine
NATR
$227M
| $543K | ﹤0.01% |
24,890
-5,100
| -17% | -$119K |
|
3135
California Water Service
CWT
$2.86B
| $542K | ﹤0.01% |
11,133
-38,440
| -78% | -$1.73M |
|
|
SLDE
3136
Slide Insurance Holdings
SLDE
$2.7B
| $541K | ﹤0.01% |
27,937
+1,561
| +6% | +$28.3K |
|
3137
Monopar Therapeutics
MNPR
$572M
| $540K | ﹤0.01% |
5,833
-19,102
| -77% | -$1.18M |
|
3138
Lightpath Technologies
LPTH
$699M
| $540K | ﹤0.01% |
33,006
-640
| -2% | -$8.93K |
|
3139
Xerox
XRX
$436M
| $539K | ﹤0.01% |
172,156
-315,543
| -65% | -$788K |
|
3140
Global Partners
GLP
$1.61B
| $539K | ﹤0.01% |
11,561
+11,438
| +9,299% | +$540K |
|
3141
Zymeworks
ZYME
$1.9B
| $539K | ﹤0.01% |
20,603
+2,229
| +12% | +$56.6K |
|
3142
Shoals Technologies Group
SHLS
$1.26B
| $538K | ﹤0.01% |
54,296
-8,679
| -14% | -$78.8K |
|
|
FIGR
3143
Figure Technology Solutions
FIGR
$7.16B
| $537K | ﹤0.01% |
17,485
-12,310
| -41% | -$412K |
|
3144
Janus International
JBI
$574M
| $537K | ﹤0.01% |
96,704
+19,972
| +26% | +$105K |
|
3145
nCino
NCNO
$2.05B
| $536K | ﹤0.01% |
32,781
-18,194
| -36% | -$299K |
|
3146
PUT
MKS Inc
MKSI
$17.6B
| $534K | ﹤0.01% |
+1,200
| New | +$376K |
|
3147
Keros Therapeutics
KROS
$230M
| $532K | ﹤0.01% |
49,704
+26,547
| +115% | +$296K |
|
3148
dLocal
DLO
$4.14B
| $530K | ﹤0.01% |
40,797
-60,862
| -60% | -$772K |
|
3149
PUT
Krispy Kreme
DNUT
$501M
| $530K | ﹤0.01% |
150,000
| – | – |
|
3150
Zevra Therapeutics
ZVRA
$656M
| $529K | ﹤0.01% |
36,893
+21,448
| +139% | +$238K |
|
Similar funds
Barclays's Q2 2026 Portfolio in Review
As of Q2 2026, Barclays held 5,723 positions worth $521B, up 25% from $416B the previous quarter. Its ten largest holdings account for 43% of the portfolio.
Barclays's Q2 2026 filing shows 722 new, 1,729 increased, 2,511 reduced and 392 closed positions. Its largest new stake was Honeywell Aerospace: 2,302,561 shares worth $509M. The largest sale was NVIDIA, an estimated $4.58B.
By sector, the portfolio is most concentrated in Miscellaneous at 55% of assets, up from 46% a quarter earlier, followed by Technology and Financials.
- Barclays's largest Q2 2026 buy was Honeywell Aerospace: 2,302,561 shares worth $509M.
- Barclays added most to iShares MSCI Emerging Markets ETF in Q2 2026, an estimated $14.1B increase.
- Barclays's biggest Q2 2026 reduction was NVIDIA, cutting an estimated $4.58B.
- Barclays fully exited Masimo in Q2 2026, selling an estimated $488M.
- Barclays's ten largest holdings make up 43% of its $521B portfolio in Q2 2026.
- Barclays opened 722 new positions and closed 392 in Q2 2026.
- Barclays's portfolio value rose 25% quarter-over-quarter to $521B.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.